<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Tryptophan catabolism, which is mediated by the enzymes indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO), produces <z:chebi fb="0" ids="28683">kynurenine</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="28683">Kynurenine</z:chebi> itself is converted by downstream enzymes into secondary catabolites </plain></SENT>
<SENT sid="2" pm="."><plain>We evaluated the serum levels of primary and secondary tryptophan catabolites in a cohort of patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="3" pm="."><plain>The <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients showed significantly higher levels tryptophan catabolites which correlated with cytopenia </plain></SENT>
<SENT sid="4" pm="."><plain>The tryptophan catabolites inhibited progenitor expansion during the in vitro culture of hematopoietic cells </plain></SENT>
<SENT sid="5" pm="."><plain>Thus, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients are characterized by high tryptophan catabolism resulting in elevated primary and <z:chebi fb="1" ids="26619">secondary metabolites</z:chebi>, which both have inhibitory effects on hematopoiesis </plain></SENT>
</text></document>